EP
KRYS icon

Edgestream Partners’s Krystal Biotech KRYS Stock Holding History

Edgestream Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,678
Closed -$2.7M – 978
2025
Q2 		$2.7M Buy
+19,678
New +$2.89M 0.08% 459
2025
Q1 		– Sell
-23,810
Closed -$3.73M – 943
2024
Q4 		$3.73M Sell
23,810
-8,447
-26% -$1.5M 0.16% 242
2024
Q3 		$5.87M Buy
+32,257
New +$6.22M 0.26% 100

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Edgestream Partners's KRYS Position: Q3 2025 in Review

Edgestream Partners sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 19,678 shares — an estimated $2.7M sold.

Edgestream Partners first reported a position in KRYS in Q3 2024 and held it in 3 quarters. The position peaked at $5.87M in Q3 2024. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • Edgestream Partners reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
  • Edgestream Partners sold 19,678 Krystal Biotech shares in Q3 2025, an estimated $2.7M.
  • Edgestream Partners first reported a position in Krystal Biotech in Q3 2024 and held it in 3 quarters.
  • Edgestream Partners's Krystal Biotech position peaked at $5.87M in Q3 2024.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Edgestream Partners's 13F filing for Q3 2025, filed 12 Nov 2025.